Extended treatment for cigarette smoking cessation: a randomized control trial

Plain-language guide to PMID 28239942 (2017): open-label randomized controlled trial study of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 28239942
Journal: Addiction (Abingdon, England)
Year: 2017
Study type: Randomized Controlled Trial
Authors: Laude JR et al. (10 authors)
DOI: 10.1111/add.13806
Registered trial: NCT01330043

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial paper looks at Therapeutic nicotine (patch, non-peptide).

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment.

Half the participants were randomized at 26 weeks to extended CBT (E-CBT) to week 48 and half to non-extended CBT (no additional CBT sessions).

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Therapeutic nicotine (patch, non-peptide) study did not mask who received what.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Two-group parallel randomized controlled trial.

Community clinic in the United States.

A total of 219 smokers (mean age: 43 years; mean cigarettes/day: 18).

The primary outcome was expired CO-confirmed, 7-day point-prevalence (PP) at 52- and 104-week follow-up.

Analyses were based on intention-to-treat.

What Was Measured

The subject headings attached to it are Bupropion, Cigarette Smoking, Cognitive Behavioral Therapy, Nicotinic Agonists, Smoking Cessation, Time and Tobacco Use Cessation Devices.

Author keywords: Abstinence, adaptive treatment, bupropion SR, clinical trial, extended treatment and nicotine dependence.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Addiction (Abingdon, England)), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.